RxDoctor Payments Data

Edward Chu, MD

Ophthalmology · San Antonio, TXNPI 1649699307

Payments from drug & device makers

$1,576in general payments, 2019–2025

Across 21 payments — averaging $75.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$752
  • Sight Sciences, Inc.$253
  • AbbVie$132
  • Alcon$112
  • E.r. Squibb & Sons, L.L.C.$112
  • Rxsight Inc$101
  • plus $115 from 2 others

What the payments were for

  • Food & beverage$1,576100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,576 in reported general payments places this provider in the 40th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$50,085
Medicare patients
144
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Restasis MultidoseCyclosporine123$102,200
RestasisCyclosporine76$87,361
RhopressaNetarsudil Mesylate61$35,702
Prednisolone Acetate279$10,064
Cyclosporine18$7,345
Latanoprost539$7,249
MoxifloxacinMoxifloxacin Hcl175$6,315
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat385$5,230
Ketorolac Tromethamine171$4,737
Travoprost25$4,424
Brimonidine Tartrate383$3,835
CombiganBrimonidine Tartrate/Timolol14$3,592
Dorzolamide Hcl179$3,061
Timolol Maleate145$1,825
Acetazolamide ErAcetazolamide23$1,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis Multidose, Restasis, Combigan$132$193,154213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →